ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%.
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR Therapeutics and Dragonfly Therapeutics, if confirmed by the ...
The Government of Punjab has announced a remarkable initiative under the Chief Minister’s “Magnificent Punjab” Tourism Internship Programme. Designed to provide professional exposure and ...
As health secretary, RFK Jr. said he would divest interests in several companies—including CRISPR Therapeutics and Dragonfly Therapeutics—within 90 days, according to a Jan. 21 disclosure ...
A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...
NASDAQ:CRSP opened at $41.51 on Wednesday. CRISPR Therapeutics AG has a one year low of $36.52 and a one year high of $91.10. The company has a market cap of $3.54 billion, a PE ratio of -14.67 ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback